News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,278 Results
Type
Article (40353)
Company Profile (307)
Press Release (652618)
Section
Business (206069)
Career Advice (1995)
Deals (35683)
Drug Delivery (87)
Drug Development (82124)
Employer Resources (168)
FDA (16243)
Job Trends (14956)
News (348428)
Policy (32697)
Tag
Academia (2570)
Alliances (49883)
Alzheimer's disease (1233)
Approvals (16173)
Artificial intelligence (134)
Bankruptcy (353)
Best Places to Work (11667)
Biotechnology (223)
Breast cancer (123)
Cancer (1132)
Cardiovascular disease (97)
Career advice (1664)
Cell therapy (242)
Clinical research (65285)
Collaboration (395)
Compensation (199)
COVID-19 (2542)
C-suite (99)
Data (1125)
Diabetes (152)
Diagnostics (6215)
Earnings (85366)
Employer resources (146)
Events (111309)
Executive appointments (313)
FDA (16785)
Funding (353)
Gene therapy (178)
GLP-1 (584)
Government (4354)
Healthcare (18907)
Infectious disease (2627)
Inflammatory bowel disease (108)
Interviews (308)
IPO (16425)
Job creations (3651)
Job search strategy (1421)
Layoffs (425)
Legal (7882)
Lung cancer (183)
Manufacturing (177)
Medical device (13225)
Medtech (13230)
Mergers & acquisitions (19334)
Metabolic disorders (404)
Neuroscience (1511)
NextGen Class of 2024 (6565)
Non-profit (4499)
Northern California (1483)
Obesity (234)
Opinion (185)
Patents (102)
People (56958)
Phase I (20339)
Phase II (28743)
Phase III (21450)
Pipeline (460)
Postmarket research (2584)
Preclinical (8620)
Radiopharmaceuticals (248)
Rare diseases (219)
Real estate (5950)
Regulatory (21739)
Research institute (2358)
Resumes & cover letters (349)
Southern California (1304)
Startups (3627)
United States (13561)
Vaccines (558)
Weight loss (170)
Date
Today (132)
Last 7 days (797)
Last 30 days (3830)
Last 365 days (36087)
2024 (33097)
2023 (40496)
2022 (51695)
2021 (56235)
2020 (54543)
2019 (47059)
2018 (35456)
2017 (32656)
2016 (32027)
2015 (38064)
2014 (31749)
2013 (26719)
2012 (28926)
2011 (29660)
2010 (27609)
Location
Africa (722)
Arizona (192)
Asia (37859)
Australia (6183)
California (3346)
Canada (1288)
China (252)
Colorado (144)
Connecticut (153)
Europe (82118)
Florida (458)
Georgia (116)
Illinois (345)
Indiana (196)
Kansas (97)
Maryland (582)
Massachusetts (2654)
Michigan (157)
Minnesota (275)
New Jersey (955)
New York (959)
North Carolina (708)
Northern California (1483)
Ohio (139)
Pennsylvania (846)
South America (1103)
Southern California (1304)
Texas (462)
Utah (90)
Washington State (361)
693,278 Results for "epivax oncology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai’s robust biologics pipeline.
December 20, 2023
·
2 min read
Press Releases
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
October 25, 2024
·
3 min read
Genetown
Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.
August 11, 2023
·
2 min read
Genetown
Providence-based “Biotech start up” EpiVax Celebrates 25th Anniversary
EpiVax, Inc. is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company.
May 17, 2023
·
3 min read
Press Releases
OneCell Diagnostics, Inc. Announces Oversubscribed Series A Funding Round to Accelerate Proprietary Cell Biopsy Technology to Democratize Precision Oncology
November 21, 2024
·
4 min read
Business
EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™
EpiVax, Inc. (“EpiVax”) and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2.
January 10, 2023
·
2 min read
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
October 31, 2022
·
2 min read
Press Releases
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals
October 24, 2024
·
5 min read
Press Releases
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
September 5, 2024
·
14 min read
Press Releases
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
November 11, 2024
·
18 min read
1 of 69,328
Next
